Our mission is to help you obtain financial freedom. Checkout Our Youtube Channel Checkout Our Youtube Channel

$NVAX Receives FDA Approval, Key Price Targets After 10%+ Intraday Rally

Novavax (NVAX) has been one of our best performing stocks that has been trading in an accumulation range between $7 and $9. I believe that NVAX is trending for an upward breakout in Q4. The FDA has approved NVAX’s COVID vaccine for patient ages 12+, and the European Union is set to make a decision in October. I believe that NVAX has promising short-term outlook that will lead to a rally with a break above $9. So far $9.18 has been a key resistance target, but I believe that NVAX will ultimately break out to the light blue resistance level at $16.21

TradingView chart:

Inline Feedbacks
View all comments

More ClearValue Insights

Default Thumbnail

Beyond Jobs: Why Recent Employment Figures May Not Sway the Fed

These past few days have been quite uncertain, especially regarding what is in store for interest rates in the U.S. But with the latest news revealing that nonfarm payrolls surged by a hefty 303,000 in March, beating expectations and showing a significant jump from the previous month, and with the unemployment rate holding steady at […]

Read More
Default Thumbnail

Against The Tide: The Contrarian View On Fed Rate Cuts

Following the Federal Reserve’s recent decision to keep rates unchanged and the suggestion of future rate cuts later in the year, there’s been a prevailing sense of optimism among many investors, with reassurances that these anticipated rate cuts will materialize eventually. However, Vanguard is offering a different view point as they are suggesting that the […]

Read More
Default Thumbnail

A recommendation.

It would certainly be helpful if the posts and contend on this site would be dated. I get tired of reading recommendations and never know how old they are. Help us to know what is new vs stale info and recommendations.

Read More